Good day ladies and gentlemen and welcome to the West Pharmaceutical Services Second Quarter 2015 Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions following at that time. [Operator Instructions] As a reminder this call is being recorded on behalf of West and is copyrighted material. It cannot be rerecorded or rebroadcast without the company's expressed permission. Your participation in this call implies your consent to our taping. If you have any objection, you may disconnect at this time. And now, I would like to [indiscernible] the meeting over to Mr. John Woolford from Westwicke Partners. Sir, you may begin.

Thank you, operator. Good morning, everyone. And welcome to West's second quarter 2015 results conference call. We issued our financial results this morning and the release has been posted in the Investor section on the company's Web site located at www.westpharma.com. If you have not received a copy of this announcement, please call Westwicke Partners at (443) 213-0500 and a copy will be sent to you immediately. Posted on the company's website under Investors on the Presentation Materials tab is a slide presentation that management will refer to in their remarks today. The presentation is in PDF format. Should you require a link to a free download of software that will enable users to view that presentation is also available on the website. I remind you that statements made by management on this call and in the presentation will contain forward-looking statements within the meaning of U.S. Federal Securities Law and that are based on management's beliefs and assumptions, current expectations, estimates and forecasts. Many of the factors that will determine the company's future results are beyond the ability of the company's control or predict. These statements are subject to known or unknown risks or uncertainties and therefore, actual results could differ materially from past results and those expressed or implied in any forward-looking statement. For a non-exclusive list of factors which could cause actual results to differ from expectations, please refer to today's press release as well as any further disclosures that company makes on related subjects in the company's 10-K, 10-Q, and 8-K reports. In addition, during today's call, management may make reference to non-GAAP financial measures, including adjusted operating profit and adjusted diluted EPS. Reconciliations and limitations of the non-GAAP financial measures to the most comparable financial results prepared in conformity to GAAP are provided in materials accompanying this morning's earnings release. At this time, I'd like to turn the call over to Eric Green, West's Chief Executive Officer. Eric?

Thank you, John and good morning everyone. Welcome to West's second quarter 2015 earnings call. I'm joined on the call this morning by Bill Federici, our Chief Financial Officer; and Mike Anderson, our Treasurer and Primary Investor Relations Contact. Today, I will review our second quarter results, full year outlook and share my reflections about the business after three months with West. Bill will then provide a deeper review into the financial performance and full year guidance, then we will open up the call for your questions. Starting with the results on Slide 3. We had a strong second quarter with reported revenues of $359.7 million, excluding a 9.9% currency headwind, sales increased 7.4% driven by demand for high value packaging components and proprietary delivery systems. Adjusted EPS of $0.47 includes $0.09 at adverse currency versus last year and would have grown by nearly 8% over the second quarter of prior year on a constant currency basis. As a reminder, second quarter of 2014 EPS set a record for West. Turning to business segment highlights for the quarter on Slide 4. Revenue in the Pharmaceutical Packaging Systems segment grew 8.5% on a constant currency basis, with double-digit growth in Europe, Asia-Pacific and South America. We continue to experience strong customer demand for the high value packaging components with sales growth of over 12% led by our newer Envision and NovaPure product lines. In our pharmaceutical delivery systems business, revenue grew 6% excluding currency and taking into account the disposition of a small tooling business in 2014. The segment was led by 9.3% growth in the proprietary delivery systems portfolio, we are just [indiscernible] excited about the prospects for SmartDose and CZ products, but the majority of the growth in this quarter came from the more mature proprietary products drug, the…

Thank you, Eric and good morning everyone. We issued our second quarter results this morning reporting net income of $27.8 million or $0.38 per diluted share. Our reported results this quarter include a $0.09 per diluted share one-time charge associated with executive retirements. Excluding this charge, our adjusted earnings per diluted share are $0.47 this quarter, $0.05 below the $0.52 per diluted share earned in the second quarter of '14. Our 2015 earnings have been adversely impacted by the continued decline in the value of the euro and most other foreign currencies in relation to the U.S. dollar. A translation of our international results into U.S. dollars for reporting purposes has reduced our reported earnings by approximately $0.09 per share as compared to the prior year second quarter and by $0.18 per share for the year-to-date June comparison. We manage our foreign currency [indiscernible] exposures and generally our local operations are naturally hedged. Turning to sales, Slide 6 shows the components of our consolidated sales increased. Excluding exchange effects, our consolidated second quarter sales of $359.7 million increased by 7.4% versus our second quarter 2014 sales. Packaging system sales increased 8.5% versus the same quarter 2014, excluding exchange. Sales price increases accounted for 1.2 percentage points in the sales increase and the favorable mix of product sold and volume increases contributed the remainder of the increase. Sales of our high value products rose 12% versus the prior year second quarter. High value products represented 45.9% of packaging systems Q2 2015 sales versus 44.4% a year ago. We continue to see strong customer demand for our product offerings that need our customers' high quality specification. Delivery system sales increased by 6% versus the prior year quarter ex-currency and excluding the 2014 divestiture of a contract tooling and services business. Sales of…

Thank you, Bill. In summary, our 7,000 colleagues around the world delivered a solid quarter and a strong first half of 2015. After my first 100 days, I am more firmly convinced that West is well position to benefit from the positive market trends with increased demand for our high value packaging components and proprietary delivery systems. In addition we are investing appropriately to meet the future needs of our customers and deliver increased shareholders value. Thank you. We now look forward to answer your questions. Operator?

Thank you. [Operator Instructions]. First question is from Larry Solow of CJS Securities. Your line is open.

Looking if you guys could just on the strong higher value [indiscernible] sales. I realize it's one quarter that doesn’t necessarily make a trend and I know some of the newer products are coming off of much smaller basis, but I guess nice to see Envision and NovaPure sort of carrying some of the growth load this quarter. Have you any color on that? Larry Solow: Looking if you guys could just on the strong higher value [indiscernible] sales. I realize it's one quarter that doesn’t necessarily make a trend and I know some of the newer products are coming off of much smaller basis, but I guess nice to see Envision and NovaPure sort of carrying some of the growth load this quarter. Have you any color on that?

Yes, we are very pleased with the results of our high value products portfolio. It continues to gain traction and acceptance in the market as more of our customers are requiring the higher quality of the end product -- the components with our end products. So we are seeing the demand continues to play well with how West is positioned and also how our operations are being optimized to support these customers in all geographies.

And then CZ vials, any update. I know you sort of -- I think you have sighted the two recent approvals, two products I think that we have heard that. Any sort of update, how -- is the development pipeline expanding? Any thoughts on that. Larry Solow: And then CZ vials, any update. I know you sort of -- I think you have sighted the two recent approvals, two products I think that we have heard that. Any sort of update, how -- is the development pipeline expanding? Any thoughts on that.

Yes Larry, the pipeline of our CZ program still remain very robust. Right now we have 13 CZ programs in formal stability studies and the outlook continues to be positive.

And just back to on the gross margin, in light of some improved visibility and it sounds like packaging systems is doing well. Thoughts on you have your targeted gross margin for the year sort of implies a bit of a contraction in the back half of the year. Is that due to maybe a little slowdown or timing related on some of the higher value products or any other reason for that? Larry Solow: And just back to on the gross margin, in light of some improved visibility and it sounds like packaging systems is doing well. Thoughts on you have your targeted gross margin for the year sort of implies a bit of a contraction in the back half of the year. Is that due to maybe a little slowdown or timing related on some of the higher value products or any other reason for that?

Yes Larry, basically it's seasonality as if you look historically that's been the case. We have the summer shutdowns for preventive maintenance for both our shops in -- our factories in Europe as well as customers' and the start up after that we see -- generally, we see that the second half margins being slightly less than the first half. For the full year, I just want to remind you that we are guiding up for margins, both at the gross line and the operating profit line.

And then just last, on SG&A, pretty decent rise if you take out the currency, it is about 12%, I know you sighted that the global timing of the sales meeting I guess this year versus last year, is that, if you take that out would SG&A look somewhat better or good? Larry Solow: And then just last, on SG&A, pretty decent rise if you take out the currency, it is about 12%, I know you sighted that the global timing of the sales meeting I guess this year versus last year, is that, if you take that out would SG&A look somewhat better or good?

Yes, there is a number of things and you hit on the one that the timing in our global sales meaning which didn’t happen and though it came at all and then there is also in the second quarter of 2014, we actually had a slight reduction in our medical costs premiums due to some experience of adjustments made by the carrier. So we actually got a benefit in the ’14 second quarter that’s not there this year. And then also on incentive compensation, we’re tracking a little ahead of our goal, so we are taking those comp adjustments that positions up, so those are the three big ones. We’re also adding some heads where we believe it makes a lot of sense in the regulatory space, our customers as the regulators and customers continue to drive towards cleaner product, we have the need for more and more regulatory expertise which is a key differentiator for West in the marketplace. So we will continue to invest in those types of expenses.

Thank you. Our next question is from Derek Brown of Bank of America. Your line is open.

Could you talk a little bit about capacity utilization and sort of how should we think about CapEx going into 2016?

Okay. So capacity utilization is a complicated story, but let me try to simplify, blow it down. On the PPS side in the business, we try to aim for an 85% or so utilization of our plans. However, that’s not a perfect signs and certain of our aspects of the capacity especially in the high value products, especially around envision and especially around washing for Westar, we are very, very tax [ph] at capacity line, we are pushing up against the 100% and that’s why you see our lead times I have been expanding. We are, as we’ve talked about we’re putting, we continue to invest very prudently in additional water capacity for Westar as well as a vision systems for envision and we’ll continue as well as clean rooms for high value products but those are the key investments we’re making which we hope in the long-term along with our network optimization programs that we’re working on for the plans, we’ll help elevate some of that strains in the plans. On the PDS side, it’s more on the contract manufacturing specifically. The utilization percentage is not nearly as high, they are in the kind of high-60s, low-70s and that’s appropriate for that kind of business and we feel very comfortable with that right now.

I think we've been surprised to just see how strong the packaging systems business has remained going forward and I would look at it otherwise down two quarters, so I guess when you sort of look at that, is this sort of growth level that you're seeing sustainable in the next year? And then sort of talking about it on the delivery system side, are you expecting to see that business accelerate?

Yes Derek, it's a really good point of packaging systems business we continue to see the outlook of the high value products to continue to be very robust. We believe we can continue to perform at similar levels that we have been performing and that's the reason I will add to continue to add capacities within the three main geographies of Asia, Europe and in U.S. Your point is valid and there are delivery devices business where we're looking at future investments that pay backs over the longer term and we're very optimistic with when we are sort of looking at the level engagement we have with the customers active programs with SmartDose, then I mentioned when it was in phase III and then also with the 13 programs with formal stability with the CD product portfolio. So it is, you are going to see it for longer term what the delivery systems business unit around.

I mean, I’ve been watching the stock and filling up for a number of years and certainly see the, always seems to be on the comp I mean is that -- are you less enthusiastic about seeing the avenue were in the past, I'm just curious in terms of your thought on that I mean on that business?

Let me start with by saying that the outlook for store remains very strong and there is a timeline for adoption by customers but what we're seeing with conversations with our clients is that the attributes allows them to be more effective in the end markets. So we believe that we have the right formula the customers uptakes are visible, there is more in the formal stability trials at this point so we're pretty optimistic about that and we'll continue to see demand in the CZ portfolio.

And could you talk a little bit just about sort of your longer term vision in terms of international expansion and sort of market shares internationally and what sort of opportunity to add growth?

Yes Derek as you know this is an area that we focused on in the past quite a bit and I believe West is well positioned to take advantage of the market opportunities in some of the more in Asia and also in Latin America. I think our position today while we do have presence with the multinational in China and India and other geographies in Asia, we do have the opportunity to see more of an expansion. Now we have had, we put investments in China, India, Singapore, but I believe that our opportunity to growing faster and it present ourselves very nicely for West. So that is an area that we will continue to focus on and put little more energy and resources around that as we go forward.

Can you just remind me in terms of the geographic split of the business, I’m blanking?

It’s rough numbers in Asia took a little under 10%.

Yes, okay.

It’s about $120 million of sales in Asia.

And who your major agent competitors?

Well, It depends obviously if you are talking about in China there are a number of companies that manufacture elastomers for drug product, if you are talking about the local markets there is a wide number, a large number. There are people that work with the multinationals we are the primary, we have market shares that are in similar to our western markets for the multinational, so in that kind of 60% to 70% range. In India it is a mix bag as well, but again we have very solid market shares with the multinationals in India as well.

And so I guess, on your expansion plans is it, do you have to come in the market with lower priced option?

I believe there is a great opportunity to bring the West quality to the market where it’s not as prevalent and if you look at the cost of our product in the entire end drug delivery is a small percentage. Therefore to increase the level of quality and the acceptance of the drugs into other local market or the global markets, there is the need to pull more West quality into that system.

Thank you. [Operator Instructions]. No further questions at this time. I’d like to turn the conference over to Eric Green for any closing remarks.

Thank you, operator. And thank you everyone for your time this morning we look forward to speaking with you again on our third quarter call in October. Thank you very much.